US 12,233,059 B2
Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
Amit Etkin, Los Altos, CA (US); Wei Wu, Los Altos, CA (US); Chao Wang, Los Altos, CA (US); Nicholas Cooper, Los Altos, CA (US); Joshua Jordan, Los Altos, CA (US); and Adam Savitz, Los Altos, CA (US)
Assigned to Alto Neuroscience, Inc., Mountain View, CA (US)
Filed by Alto Neuroscience, Inc., Los Altos, CA (US)
Filed on May 21, 2024, as Appl. No. 18/670,637.
Application 18/670,637 is a continuation in part of application No. 18/528,486, filed on Dec. 4, 2023.
Claims priority of provisional application 63/579,547, filed on Aug. 30, 2023.
Claims priority of provisional application 63/386,137, filed on Dec. 5, 2022.
Prior Publication US 2024/0307380 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 31/19 (2006.01); A61K 31/53 (2006.01); A61K 33/00 (2006.01); A61P 25/24 (2006.01); A61B 5/16 (2006.01); A61B 5/374 (2021.01)
CPC A61K 31/496 (2013.01) [A61K 9/0053 (2013.01); A61K 31/19 (2013.01); A61K 31/53 (2013.01); A61K 33/00 (2013.01); A61P 25/24 (2018.01); A61B 5/165 (2013.01); A61B 5/374 (2021.01)] 20 Claims
 
1. A method of treating bipolar depression in a human patient having objectively determined impaired learning and/or memory comprising orally administering to the patient from about 40 to about 240 mg of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone or a pharmaceutically acceptable salt thereof daily.